Clark

Researchers are studying familial hypercholesterolemia and related lipid disorders to improve treatment and reduce cardiovascular risks. The study aims to enhance lipid disorder management by partnering with primary care providers and using electronic health records to identify high-risk patients. The goal is to develop a prevention model that integrates treatment guidelines at the practice level, focusing on lowering LDL cholesterol levels in affected individuals. Participants with high LDL-C levels, especially those with familial hypercholesterolemia or related conditions, will receive supportive care through a comprehensive outreach approach. This includes database screening, secure communication with healthcare providers, genetic testing encouragement, education, medication adherence support, routine lab testing, specialist referrals, and follow-up visits either in person or virtually. Additional consultations with pharmacists, nutritionists, genetic counselors, or specialists may be provided to manage coexisting conditions. During the study, patients LDL-C levels will be monitored, with the primary measure being the proportion maintaining LDL-C below 100 mgdL six months after enrollment. Secondary outcomes include achieving LDL-C levels below 75 and 55 mgdL. The study involves ongoing medical management, routine lab tests, and access to integrated care resources, aiming to improve lipid control and reduce cardiovascular risks over time.

Researchers are evaluating a drug called cemiplimab for treating early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. Cemiplimab helps the immune system attack cancer cells by targeting a protein called PD-1 on immune cells. The studys main goal is to compare how well cemiplimab works when injected directly into the lesion versus standard surgery. Participants will be randomly assigned to receive either cemiplimab injected into the lesion or undergo primary surgery using techniques like Mohs surgery or other complete margin assessment methods. The study will assess side effects and how well cemiplimab performs compared to surgery in treating the cancer. During the study, participants will be monitored for event-free survival up to 3 years. Researchers will also evaluate lesion response, treatment-related adverse events, and sizes of surgical or biopsy defects. The total participation period extends up to 3 years, with regular assessments to track safety and treatment effectiveness.